Medicus & Gorlin Alliance Seek Compassionate Use for Skinject
An interim analysis from Medicus Pharma’s randomized, double-blind, placebo-controlled Phase 2 study (SKNJCT-003) reported more than 60% clinical clearance...
eClinical Tech News
Avalo Completes Enrollment for Phase 2 LOTUS Trial in HS
Avalo Therapeutics has fully enrolled its Phase 2 LOTUS study of AVTX-009 in hidradenitis suppurativa, randomizing roughly 250 adults...
BlossomHill’s Promising Early Trial Data for NSCLC Drug
In the dose escalation of the first-in-human SOLARA study, BH-30643 was administered to 39 previously treated EGFR-mutant NSCLC patients...
Flare Therapeutics Reveals FX-909 Phase 1 Study Results
In Part A of a Phase 1 study in advanced urothelial carcinoma (UC), FX-909 monotherapy produced five objective responses...
Successful Phase 1 Data for REM-422 in Cancer Patients
REM-422, an oral small-molecule mRNA degrader targeting MYB, produced a 43% overall response rate by RECIST in the efficacy...
Halda’s New Prostate Cancer Drug Shows Encouraging Activity
In a first-in-human Phase 1/2 study of HLD-0915 in metastatic castration-resistant prostate cancer, 31% of all 31 treated patients...
New TDP-43 PET Tracer: A Breakthrough for Precision Medicine
Preclinical data published in Nature Communications characterize AC Immune’s fluorine-18–labeled TDP-43 PET tracer, ACI-19626, showing high affinity for pathological...
Sobi’s Commitment to Rare Disease Care at ACR Convergence
In post-hoc analyses of the Phase 3 DISSOLVE trials in uncontrolled gout, nanoencapsulated sirolimus plus pegadricase (NASP) drove rapid...
Promising Phase 1 Data for KYV-101 in Rheumatoid Arthritis
In the Phase 1 portion of an investigator-initiated Phase 1/2 study in treatment-refractory rheumatoid arthritis, six patients received a...
New Hope for Nocturnal GERD: Successful Voquezna Trial
At week 4 in the Phase 3 pHalcon-NERD-301 study, patients on vonoprazan achieved mean percentages of heartburn-free nights of...